Antithrombin III Protects Against Contrast-Induced Nephropathy

Area of Science:

• Nephrology
• Cardiology
• Hematology

Background:

• Antithrombin III (ATIII) is a key anticoagulant.
• ATIII insufficiency has been linked to exacerbated renal ischemia-reperfusion injury.
• Contrast-induced nephropathy (CIN) is a significant clinical concern following angiography.

Purpose of the Study:

• To investigate the correlation between ATIII levels and CIN in patients.
• To evaluate the therapeutic potential of ATIII in a rat model of CIN.

Main Methods:

• Retrospective analysis of patients undergoing coronary angiography to assess the relationship between baseline ATIII activity and acute kidney injury (AKI).
• Administration of ATIII (500 μg/kg) intravenously before or after AKI induction in Sprague-Dawley rats.
• Assessment of renal function markers (serum creatinine, blood urea nitrogen), histological damage, inflammation, oxidative stress, apoptosis, and renal blood flow.

Main Results:

• Patients with lower ATIII activity exhibited a higher incidence of AKI post-coronary angiography.
• ATIII treatment in rats significantly attenuated increases in serum creatinine and blood urea nitrogen.
• ATIII administration reduced renal histological injury, inflammation, oxidative stress, and apoptosis, while improving renal blood flow.

Conclusions:

• ATIII deficiency is associated with increased risk of CIN.
• ATIII demonstrates protective effects against CIN in a preclinical model.
• ATIII attenuates CIN by mitigating inflammation, oxidative stress, and apoptosis, and enhancing renal perfusion.